Fortress Biotech, Inc. (FBIO) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 68.47M USD | |
| Cost of products and services | 23.56M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $68.47M | $23.56M | (m) |
| 2026-03-31 | (m) | $66.16M | $22.35M | (m) |
| 2025-12-31 | (m) | $63.26M | $20.92M | (m) |
| 2025-09-30 | (m) | $62.30M | $20.16M | (m) |
| 2025-06-30 | (m) | $59.30M | $18.88M | (m) |
| 2025-03-31 | (m) | $57.78M | $19.67M | (m) |
| 2024-12-31 | (m) | $57.67M | $20.88M | (m) |
| 2024-09-30 | (m) | $62.50M | $24.66M | (m) |
| 2024-06-30 | (m) | $82.62M | $25.80M | (m) |
| 2024-03-31 | (m) | $85.11M | $27.03M | (m) |
| 2023-12-31 | (m) | $84.51M | $26.66M | (m) |
| 2023-09-30 | (m) | $80.97M | $28.36M | (m) |
| 2023-06-30 | (m) | $62.75M | $29.16M | (m) |
| 2023-03-31 | (m) | $64.25M | $29.02M | (m) |
| 2022-12-31 | (m) | $75.74M | $30.77M | (m) |
| 2022-09-30 | (m) | $77.61M | $32.58M | (m) |
| 2022-06-30 | (m) | $82.17M | $36.53M | (m) |
| 2022-03-31 | (m) | $81.13M | $36.38M | (m) |
| 2021-12-31 | (m) | $68.79M | $32.08M | (m) |
| 2021-09-30 | (m) | $64.26M | $26.84M | (m) |
| 2021-06-30 | (m) | $52.65M | $19.05M | (m) |
| 2021-03-31 | (m) | $44.27M | $14.69M | (m) |
| 2020-12-31 | (m) | $45.60M | $14.59M | (m) |
| 2020-09-30 | (m) | $42.98M | $13.87M | (m) |
| 2020-06-30 | (m) | $43.28M | $13.20M | (m) |
| 2020-03-31 | (m) | $43.07M | $12.46M | (m) |
| 2019-12-31 | (m) | $36.63M | $10.53M | (m) |
| 2019-09-30 | (m) | $34.49M | $8.55M | (m) |
| 2019-06-30 | (m) | $29.89M | (m) | (m) |
| 2019-03-31 | (m) | $27.46M | $6.54M | (m) |
| 2018-12-31 | (m) | $26.88M | $6.13M | (m) |
| 2018-09-30 | (m) | $228.27M | (m) | (m) |
| 2018-06-30 | (m) | $211.46M | (m) | (m) |
| 2018-03-31 | (m) | $198.33M | (m) | (m) |
| 2017-12-31 | (m) | $187.58M | (m) | (m) |
| 2017-09-30 | (m) | $154.88M | (m) | (m) |
| 2017-06-30 | (m) | $108.97M | (m) | (m) |
| 2017-03-31 | (m) | $60.50M | (m) | (m) |
| 2016-12-31 | (m) | $16.48M | (m) | (m) |
| 2016-09-30 | (m) | $4.20M | (m) | (m) |
| 2016-06-30 | (m) | $3.25M | (m) | (m) |
| 2016-03-31 | (m) | $1.02M | (m) | (m) |
| 2015-12-31 | (m) | $863.00K | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $0.00 | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |